Research programme: protein kinase inhibitors - Qurient Therapeutics
Alternative Names: Axl kinase inhibitors - Qurient Therapeutics; CDK7 inhibitors - Qurient Therapeutics; CSF1R inhibitors; Cyclin-dependent kinase 7 inhibitors - Qurient Therapeutics; Mer kinase inhibitors - Qurient Therapeutics; Q-701Latest Information Update: 07 Jun 2022
At a glance
- Originator Max Planck Innovation; The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
- Developer Max Planck Innovation; Qurient Co; The Lead Discovery Center
- Class Anti-inflammatories; Antineoplastics; Antivirals
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- Discontinued Inflammation; Viral infections
Most Recent Events
- 07 Jun 2022 Preclinical trials in Solid tumours in South Korea (PO) (Vichem Chemie pipeline, June 2022)
- 24 May 2019 Discontinued for Inflammation in South Korea (unspecified route) (Qurient Therapeutics pipeline, May 2019)
- 24 May 2019 Discontinued for Viral infections in South Korea (unspecified route) (Qurient Therapeutics pipeline, May 2019)